Article Text

Download PDFPDF
Original research
Endovascular treatment of intracranial aneurysms using the Derivo Embolization Device: a multicenter experience
  1. Galileu Chagas Lourenço1,
  2. François Dantas1,
  3. Tiago Silva e Carvalho1,
  4. Róberti Uili Rodrigues Firmino1,
  5. Marcelo Quesado Filgueiras Filho1,
  6. Renato Tavares Tosello2,
  7. Cláudio José Leão3,
  8. Ronie Leo Piske4,
  9. Rogério Zenóbio Darwich1
  1. 1Department of Interventional Neuroradiology, Biocor Instituto, Nova Lima, Minas Gerais, Brazil
  2. 2Centro de Neuro-Angiografia, Hospital Beneficencia Portuguesa de Sao Paulo, Sao Paulo, Brazil
  3. 3Department of Interventional Neuroradiology, Hospital Geral de Goiânia Dr Alberto Rassi, Goiania, Brazil
  4. 4Department of Interventional Neuroradiology, Beneficência Portuguesa de São Paulo, Sao Paulo, Brazil
  1. Correspondence to Dr Galileu Chagas Lourenço, Department of Interventional Neuroradiology, Biocor Instituto, Nova Lima, Minas Gerais, Brazil; galileucl{at}


Background Flow diversion is the first-line treatment for several types of intracranial aneurysms. We report on a large series of patients treated with the Derivo Embolization Device who underwent a 1-year angiographic control follow-up.

Methods We performed a multicenter retrospective analysis of prospectively collected data, designed to evaluate the clinical and angiographic results of treatment of intracranial aneurysms with the Derivo Flow Diverter. The primary endpoint was complete occlusion of the aneurysm within 12 months, which was evaluated using DSA. The secondary endpoint was the absence of any serious adverse events. Univariate and multivariate logistic regression analyses were performed to analyze the data.

Results The study was conducted from December 2016 to September 2019 and enrolled 127 patients with 177 intracranial aneurysms, treated at three different centers. Efficacy at 6 months was 70.1% (122/174) for total occlusion and 87.3% (152/174) for favorable occlusion and, at 12 months, it was 83.3% (145/174) for total occlusion and 97.7% (170/174) for favorable occlusion. Regarding safety concerns, 97.6% (124/127) of patients did not experience severe adverse effects during the follow-up period of 12 months, and there was no procedure-related mortality.

Conclusions The Derivo Embolization Device, achieving a total occlusion rate of 83.3% and a favorable occlusion rate of 97.7% in a 1-year angiographic control study of 174 aneurysms with minor morbidity and no intervention-related mortality, is a safe and effective treatment for intracranial aneurysms.

  • flow diverter
  • aneurysm
  • stroke
  • stent

Data availability statement

Data are available upon reasonable request.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available upon reasonable request.

View Full Text


  • Contributors RZD, CJL, RTT, and TSeC participated in the conception and design of the study. TSeC, RZD, RTT, RLP (deceased), and CJL monitored data collection for the study, analysed the data, and drafted the paper. GCL, FD, TSeC, RURF, MQFF, and RZD analysed the data and drafted and revised the draft paper. All authors read and approved the final version of the manuscript. RZD is the guarantor.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.